# The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment

Study · id `cardio:ct-nct05803759` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05803759](<https://clinicaltrials.gov/study/NCT05803759>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05803759

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05803759. Randomized; double masking; primary purpose treatment. Start 2023-04-10 (actual); primary completion 2024-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05803759, source copy `cardio:ctgov-nct05803759-2023-04-19`, retrieved 2026-10-26)
- Started: 2023-04-10 (actual) (ClinicalTrials.gov record NCT05803759, source copy `cardio:ctgov-nct05803759-2023-04-19`, retrieved 2026-10-26)
- Primary completion: 2024-03-31 (anticipated) (ClinicalTrials.gov record NCT05803759, source copy `cardio:ctgov-nct05803759-2023-04-19`, retrieved 2026-10-26)
- Completion: 2025-03-31 (anticipated) (ClinicalTrials.gov record NCT05803759, source copy `cardio:ctgov-nct05803759-2023-04-19`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT05803759, source copy `cardio:ctgov-nct05803759-2023-04-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05803759-2023-04-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment
- Acronym: TEA-CART
- Condition: Myocardial Ischemia
- Condition: Coronary Artery Bypass Grafting
- Condition: Coronary Arteriosclerosis
- Condition: Percutaneous Coronary Revascularization
- Intervention (Dietary supplement): Allicor
- Intervention (Drug): Placebo
- Lead sponsor: Institute for Atherosclerosis Research, Russia
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Institute for Atherosclerosis Research, Russia (`cardio:org-institute-for-atherosclerosis-research-russia`)

## Provenance

Content hash: 0c79fd7f3877e4313393c310b62396a9ecb3568704eaa84eca4112feba53a542
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
